Drugs / LP-184
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05933265 | Jun 2023 → Jul 2026 overdue | glioblastoma, metastatic neoplasm, non-small cell lung carcinoma, pancreatic adenocarcinoma +1 | Lantern Pharma Inc. | Active not recruiting | Met primary |
News releases announcing trial results or a regulatory action · 30
| Date | Issuer | Release |
|---|---|---|
| 2026-08-14 | Lantern Pharma Inc. | Regulatory Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update lanternpharma.com ↗
EMA Clears LP-184, zirdafulven, for Biomarker-Selected Bladder Cancer Trial |
| 2026-07-28 | Lantern Pharma Inc. | Regulatory Lantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Cancer lanternpharma.com ↗
an investigator-initiated Phase 1b/2 clinical trial of its lead drug candidate LP-184 (zirdafulven) in advanced, recurrent bladder cancer has been cleared by the European Medicines Agency (EMA). |
| 2026-03-27 | Lantern Pharma Inc. | Regulatory Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001 lanternpharma.com ↗
Lantern Pharma Inc. (NASDAQ: LTRN) and its CNS-oncology focused wholly owned subsidiary Starlight Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for STAR-001 in a planned Phase 1 pediatric clinical trial (IND No. 179145). |
| 2025-12-03 | Lantern Pharma Inc. | Results Lantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision Oncology Program into Multiple Biomarker-Guided Phase 1b/2 Trials lanternpharma.com ↗
The clinical trial demonstrated encouraging durable disease control in 63 heavily pre-treated patients with advanced solid tumors, many of which had DNA damage repair (DDR) pathway deficiencies. |
| 2025-09-16 | Lantern Pharma Inc. | Results Lantern Pharma’s LP-184 Phase 1a Clinical Trial Achieves All Primary Endpoints with Robust Safety Profile and Promising Antitumor Activity in Multiple Advanced Solid Tumors lanternpharma.com ↗
The trial met all primary endpoints, demonstrating a favorable safety and pharmacokinetic (PK) profile, and early signs of antitumor activity. |
| 2025-08-06 | Lantern Pharma Inc. | Regulatory Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial lanternpharma.com ↗ |
| 2025-05-29 | Lantern Pharma Inc. | Results Lantern Pharma's LP-184 Shows Promising In Vivo Activity in Atypical Teratoid Rhabdoid Tumors (ATRT) at SNO Pediatric Conference, Further Validating Rare Pediatric Disease Designation and Pathway to Clinical Trials lanternpharma.com ↗
The data demonstrated that LP-184, a next-generation acylfulvene clinical-stage drug candidate, significantly extended survival in mouse models of ATRT. |
| 2025-05-12 | Lantern Pharma Inc. | Regulatory Lantern Pharma Secures FDA Clearance for Planned Phase 1b/2 Trial of LP-184 in Biomarker-Defined, Treatment-Resistant NSCLC Patients with High Unmet Clinical Need lanternpharma.com ↗
The FDA has cleared the LP-184 investigational new drug (IND) application amendment for the treatment of a biomarker defined patient population of non-small cell lung cancer (NSCLC). |
| 2025-05-05 | Lantern Pharma Inc. | Regulatory Lantern Advances Drug Candidate LP-184 with IND Clearance for Phase 1b/2 Clinical Trial in Triple Negative Breast Cancer (TNBC) lanternpharma.com ↗
The FDA has cleared the investigational new drug (IND) application of LP-184 in triple negative breast cancer (TNBC) treatment – a novel small molecule advanced and developed with Lantern’s AI platform, RADR ® |
| 2024-12-03 | Lantern Pharma Inc. | Regulatory Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC) lanternpharma.com ↗
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development, today announced that the FDA has granted Fast Track Designation for investigational drug candidate, LP-184, for treatment of Triple Negative Breast Cancer (TNBC). |
| 2024-11-26 | Lantern Pharma Inc. | Results Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality lanternpharma.com ↗
Preclinical data, including in previously published research by Lantern Pharma, demonstrates up to 6-fold increase in GBM cell sensitivity when LP-184 is combined with spironolactone. |
| 2024-10-15 | Lantern Pharma Inc. | Regulatory Lantern Pharma’s Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA lanternpharma.com ↗
today announced that the FDA has granted Fast Track Designation for investigational drug candidate, LP-184, for treatment of Glioblastoma. |
| 2024-09-23 | Lantern Pharma Inc. | Regulatory Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children’s Cancers lanternpharma.com ↗
Lantern Pharma was granted the rare pediatric disease designation (RPDD) for drug-candidate, LP-184, in three cancer indications: Malignant Rhabdoid Tumors, Rhabdomyosarcoma, and Hepatoblastoma. |
| 2024-08-07 | Lantern Pharma Inc. | Results Lantern Pharma Highlights Promising Preclinical Results of LP-184’s Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024 lanternpharma.com ↗
LP-184 seems to potentiate anti-PD1 response in a mouse model of TNBC that is non-hypermutated and resistant to immunotherapy in the absence of LP-184. |
| 2023-10-03 | Lantern Pharma Inc. | Results Lantern Pharma Announces Publication in Clinical Cancer Research Highlighting the Enhanced Efficacy of LP-184 in Glioblastoma lanternpharma.com ↗ |
| 2023-06-12 | Lantern Pharma Inc. | Regulatory Lantern Pharma Receives FDA Clearance of IND Application for Drug Candidate LP-184 in Solid Tumors lanternpharma.com ↗
today announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for LP-184, which is being developed for multiple advanced solid tumors and central nervous system (CNS) cancers. |
| 2022-12-13 | Lantern Pharma Inc. | Results Lantern Pharma Announces Development of Drug Candidate LP-184 for Triple Negative Breast Cancer (TNBC) at the San Antonio Breast Cancer Symposium (SABCS) lanternpharma.com ↗
In all 10 TNBC PDX models, LP-184 treatment led to complete and durable tumor regression of 107-141%. |
| 2022-11-22 | Lantern Pharma Inc. | Results Lantern Pharma Announces Positive Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-184 for Glioblastoma at the Society for Neuro-Oncology Annual Meeting lanternpharma.com ↗
In our SNO poster, we demonstrated the exquisite in vitro/in vivo efficacy of LP-184 towards GBM as a single agent or in combination with spironolactone. |
| 2022-09-14 | Lantern Pharma Inc. | Results Lantern Pharma to Present Positive Preclinical Data on the Efficacy of LP-184 for Pancreatic Cancer at the AACR Special Conference for Pancreatic Cancer lanternpharma.com ↗
After two rounds of LP-184 treatment, the ATR and BRCA1 pancreatic cancer mouse models had tumor growth inhibitions of 140% and 112%, respectively. |
| 2022-03-14 | Lantern Pharma Inc. | Results Lantern Pharma to Present Positive Preclinical Data on the Effectiveness of LP-184 in Brain Metastases at the American Association of Cancer Research (AACR) Annual Meeting lanternpharma.com ↗
LP-184 demonstrated anti-tumor activity in brain metastases cell models from lung, skin, and breast cancers. |
| 2022-01-24 | Lantern Pharma Inc. | Regulatory Lantern Pharma Receives Rare Pediatric Disease and Orphan Drug Designations for LP-184 for the Treatment of Atypical Teratoid Rhabdoid Tumor (ATRT) - an Aggressive and Rapidly Growing Form of Cancer of the Central Nervous System lanternpharma.com ↗
Receiving Rare Pediatric Disease Designation from the FDA underscores the critical value of our growing focus on pediatric oncology indications at Lantern and represents another significant milestone for the LP-184 program. |
| 2021-11-11 | Lantern Pharma Inc. | Results Lantern Pharma Announces Abstract on Effectiveness of LP-184 in Glioblastoma Accepted for Presentation at the Society for Neuro-Oncology 2021 Annual Meeting lanternpharma.com ↗
The abstract submitted by Lantern Pharma and researchers at The Kennedy Krieger Institute affiliated with Johns Hopkins School of Medicine describes work demonstrating promising efficacy of LP-184 in multiple in vitro and in vivo glioblastoma models. |
| 2021-08-30 | Lantern Pharma Inc. | Regulatory FDA Grants Lantern Pharma Additional Orphan Drug Designation for Drug Candidate LP-184 in Glioblastoma Multiforme & Malignant Gliomas lanternpharma.com ↗
today announced that the U.S. Food and Drug Administration (FDA) has granted LP-184 Orphan Drug Designation (ODD) for the treatment of glioblastoma multiforme (GBM) and other malignant gliomas. |
| 2021-08-19 | Lantern Pharma Inc. | Results Lantern Pharma Announces Positive Preclinical Data in Glioblastoma (GBM) with Drug Candidate LP-184 and Expands GBM Research Collaboration lanternpharma.com ↗
Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company, announced today that a successful preclinical study has shown its drug candidate LP-184 is able to inhibit tumor growth and improve survival in animal models of glioblastoma (GBM). |
| 2021-08-16 | Lantern Pharma Inc. | Results Lantern Pharma Announces Abstract on Effectiveness of LP-184 in Pancreatic Cancers Accepted for Presentation at the AACR Virtual Special Conference: Pancreatic Cancer lanternpharma.com ↗
The abstract submitted by Lantern Pharma and researchers at Fox Chase Cancer Center describes work demonstrating promising efficacy of LP-184 in multiple in vitro and in vivo pancreatic cancer models. |
| 2021-08-11 | Lantern Pharma Inc. | Regulatory FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-184 in the Treatment of Pancreatic Cancer lanternpharma.com ↗
Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR ® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the U.S. Food and Drug Administration (FDA) has granted LP-184 Orphan Drug Designation for the treatment of pancreatic cancer. |
| 2021-07-20 | Lantern Pharma Inc. | Results Lantern Pharma Announces Significant Positive Preclinical Data in Pancreatic Cancer With Drug Candidate LP-184 lanternpharma.com ↗
Preclinical data demonstrated that the drug candidate, LP-184, demonstrated significant and rapid pancreatic tumor shrinkage, by over 90%, in in-vivo mouse models in 8 weeks. |
| 2021-04-26 | Lantern Pharma Inc. | Results Lantern Pharma Announces Publication Detailing Preclinical Results of Drug Candidate, LP-184, in a Spectrum of Drug-Resistant Lung Cancers in the Journal Oncotarget lanternpharma.com ↗
LP-184 shows nanomolar potency in in vitro lung cancer models that are resistant to other cancer drugs |
| 2021-03-23 | Lantern Pharma Inc. | Results Lantern Pharma to Present New Data Supporting the Advancement of LP-184 at the AACR Virtual Annual Meeting 2021 lanternpharma.com ↗
Lantern's poster will highlight the spectrum of DNA damage repair defects, occurring in 25-30% of metastatic castration resistant prostate cancer (mCRPC) patients, against which LP-184 shows nanomolar potency. |
| 2020-12-15 | Lantern Pharma Inc. | Results Lantern Pharma Announces Scientific & Preclinical Data Indicating Blood Brain Barrier Permeability for Drug Candidate LP-184 in Glioblastoma and Potentially Other CNS Cancers lanternpharma.com ↗
Lantern Pharma (NASDAQ: LTRN ), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform drug discovery and development, and identify patients who will benefit from its portfolio of targeted oncology therapeutics, announced today new scientific data that substantiates blood brain barrier permeability (BBB) for its drug candidate LP-184. |
All press releases naming this drug 42 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LP-184 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05933265 ↗ |
| Modality | Small molecule | “LP-184 is a small molecule alkylating agent causing tumor cell death through DNA damage.” NCT05933265 ↗ |
| Route | Intravenous | “Eligible patients with advanced refractory solid tumors were enrolled to receive LP-184 intravenously on days 1 and 8 of each 21-day cycle.” PMID 42410111 ↗ Jul 2026 |